Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum.
Kavanagh, D; Ardissino, G; Brocklebank, V; Bouwmeester, R N; Bagga, A; Ter Heine, R; Johnson, S; Licht, C; Ma, A L T; Noris, M; Praga, M; Rondeau, E; Sinha, A; Smith, R J H; Sheerin, N S; Trimarchi, H; Wetzels, J F M; Vivarelli, M; Van de Kar, N C A J; Greenbaum, L A
Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.
↧
